The global cell expansion market was valued at USD 17.75 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 12.85% from 2023 to 2030. This growth is primarily driven by advancements in automated solutions for cell expansion, the increasing demand for cell therapy products (CTPs), and the development of gene therapies and other biologics. Automation in the cell expansion process plays a crucial role in minimizing manpower and costs, while simultaneously enhancing the reliability and efficiency of production systems, leading to more robust and consistent processes.

As the cell expansion market evolves, technological advancements are not only improving the scalability and cost-effectiveness of production but also helping ensure higher product quality and efficiency. The demand for gene therapies and biologics is growing, especially in the treatment of complex diseases, and this is driving the need for more effective and optimized cell expansion solutions.

For example, in January 2021, Thermo Fisher Scientific introduced the Gibco CTS OpTmizer Pro Serum-Free Media platform, a specialized solution aimed at improving the development and expansion of human T lymphocytes for cell therapy developers working with allogeneic workflows. This platform is specifically designed to target donor cell metabolism, making it ideal for developing off-the-shelf, allogeneic cell therapies. By eliminating the need for serum and providing a more controlled environment for cell growth, this serum-free media platform offers a more cost-effective, scalable, and reliable solution for cell therapy manufacturing.

This product is a significant advancement in addressing the manufacturing challenges faced by developers of allogeneic therapies, where donor variability and the need for scalable production are key concerns. The introduction of such innovations by industry leaders helps to ensure that companies are better equipped to meet the increasing demand for cell-based therapies and biologics globally.

Gather more insights about the market drivers, restrains and growth of the Cell Expansion Market

Regional Insights

North America

In 2022, North America accounted for the largest revenue share of 39.0% in the global cell expansion market. The region is expected to maintain its leading position over the forecast period due to a combination of factors, including increased funding from both government agencies and private organizations. These funding initiatives are critical in accelerating the manufacturing of stem cells and the development of regenerative medicines and cellular therapy products, which are driving the demand for cell expansion platforms in North America.

The investment in regenerative medicine and cell therapies in the region is expected to continue to grow, as the need for more effective treatments for conditions such as cancer, neurological disorders, and cardiovascular diseases increases. In addition, the presence of key players in the biotechnology and pharmaceutical industries, along with a well-established healthcare infrastructure, further bolsters North America's dominance in the market. The ongoing focus on stem cell research and biologics development will continue to fuel the demand for advanced cell expansion technologies in the coming years.

Asia Pacific

The Asia Pacific region is projected to experience the fastest compound annual growth rate (CAGR) of over 15.0% during the forecast period. This rapid growth can be attributed to the increasing efforts of local pharmaceutical and biotechnology companies in the region to develop and commercialize their cellular therapies. As the biopharmaceutical sector in countries like India, China, and Japan expands, the need for advanced cell expansion technologies to support the production of cell therapies is becoming more pronounced.

A key example of the region’s growing focus on cellular therapies is the collaboration between Alkem Laboratories and Stempeutics in September 2022, which led to the launch of “StemOne”, the first off-the-shelf cell therapy product for treating knee osteoarthritis in India. The product received regulatory approval from the Drugs Controller General of India (DCGI), marking the first approval of an allogeneic cell therapy product for commercial use in the country. This significant development reflects the growing investment in regenerative medicine and cell therapy in India and is expected to further drive the demand for cell expansion platforms in the region.

The Asia Pacific market is also supported by factors such as increasing healthcare spending, advances in biotechnology, and the growing prevalence of chronic diseases. As companies in this region continue to make strides in developing new cell therapies and biologics, the need for advanced cell expansion solutions will continue to grow.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global biologics market size was valued at USD 461.74 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 10.3% from 2023 to 2030. 

• The global cell therapy market size was estimated at USD 4.74 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 22.66% from 2024 to 2030.

Key Companies & Market Share Insights

The cell expansion market is highly competitive, with several key players focusing on expanding their market presence through a variety of strategies, including collaborations, partnerships, product development, and expansion into untapped regions. To maintain a competitive edge, these companies are increasingly leveraging cutting-edge technologies and innovative solutions to meet the growing demand for cell-based therapies.

Strategic Collaborations and Developments

1. STEMCELL Technologies and Applied Cells Inc. entered into a partnership in April 2022 to create an innovative solution for cell separation. The collaboration combined STEMCELL’s EasySep kits with Applied Cells’ MARS platform to enhance the ease and automation of isolating cells from different biological samples, such as whole blood, bone marrow, apheresis products, and tissues. This advancement will improve the efficiency and effectiveness of cell isolation for both research and medical purposes, significantly enhancing the overall cell expansion process.

2. In May 2023panCELLa and BioCentriq signed a research agreement to explore stem cell-derived Natural Killer (NK) cell expansion technology. The collaboration aims to evaluate panCELLa’s genetically engineered feeder cells, which are designed to enhance the expansion rate, total yield, and potency of NK cells. NK cells have gained attention for their role in immunotherapy, particularly in treating cancers, and the collaboration is expected to improve the efficiency of NK cell production, facilitating the development of new therapies.

Key Companies in the Cell Expansion Market

The global cell expansion market is driven by a number of leading companies that specialize in providing innovative products and solutions to support the production of cell therapy products. Some of the prominent players in the market include:

• Thermo Fisher Scientific, Inc.

• Corning Incorporated

• Merck KGaA

• Miltenyi Biotec

• BD (Becton, Dickinson and Company)

• Terumo BCT, Inc.

• Sartorius AG

• Takara Bio Inc.

• TRINOVA BIOCHEM GmbH

• upcyte technologies GmbH

Order a free sample PDF of the Cell Expansion Market Intelligence Study, published by Grand View Research.